Difference between revisions of "Part:BBa K5036021"

(Part Description)
 
(6 intermediate revisions by the same user not shown)
Line 8: Line 8:
  
 
This part is fused with GAL4, dcas9(c), VP64. it acts as a powerful transcription activator where it induce transcription and increased gene expression so after receptor activation, it will be directed with dCas9,VP64 and GAL4 to increases expression of YAP.
 
This part is fused with GAL4, dcas9(c), VP64. it acts as a powerful transcription activator where it induce transcription and increased gene expression so after receptor activation, it will be directed with dCas9,VP64 and GAL4 to increases expression of YAP.
 +
==Literature Characterization==
 +
Three AAV-2 vectors were created by inserting different promoters (CMV enhancer, PDGF, or a hybrid of the two) into a plasmid containing a firefly luciferase gene. These plasmids were then combined with two other plasmids (pAAV-RC and pHelper) and introduced into HEK293 cells which resulted in the production of three AAV-2 vectors, named AAV-CMV enhancer-luc, AAV-PDGF-luc, and AAV-CMV enhancer/PDGF-luc.
 +
The researchers tested how well the three AAV-2 vectors infected different types of cells, including primary rat brain cells (neurons and glial cells), and mouse and human cell lines (C17.2 and NT2-N) that had been grown to become neurons. They used a high dose (MOI of 1000) to ensure maximum infection.
 +
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
 +
width:50%;
 +
height:auto;
 +
position: relative;
 +
top: 50%;
 +
left: 25%;
 +
transform: translate( -50%);
 +
padding-bottom:25px;
 +
padding-top:25px;
 +
"src="https://static.igem.wiki/teams/5036/parts/2024-09-15-092841.png">
 +
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 +
lang=EN style='font-size:11.0pt;line-height:115%'>AAV-2 vectors containing a hybrid CMV enhancer/PDGF promoter significantly increased luciferase gene expression in primary cortex neurons compared to vectors with the CMV enhancer/P promoter or the PDGF promoter alone respectively, at both 4 and 7 days post-transduction (Figures 1A and 1B).. This effect was seen in both mouse and human neuronal cells. However, in primary glial cells, the CMV enhancer/P promoter was more effective than the hybrid promoter(Figure 1C). These results suggest that the hybrid promoter retains its neuronal specificity.
 +
  </span></p></div></html>
 +
==Characterization by Mathematical Modeling==
 +
The model provides the activation kinetics of  CMV trans-enhancer which occurs subsequent to upon releasing of the d-Cas9 system to initiate the transcription of the YAP-1.The result shows increase in transcription activation level of YAP-1 which implies successful CMV trans-enhancer activation based on parametric values from literature
 +
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
 +
width:75%;
 +
height:auto;
 +
position: relative;
 +
top: 50%;
 +
left: 35%;
 +
transform: translate( -50%);
 +
padding-bottom:25px;
 +
padding-top:25px;
 +
"src="https://static.igem.wiki/teams/5036/parts-modeling/21.png
 +
">
 +
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 +
lang=EN style='font-size:11.0pt;line-height:115%'>Graph(1).  Illustrates the relation between activation level of CMV trans-enhancer (Blue line) for increasing the transcription level of YAP-1 (Black line)
 +
.  </span></p></div></html>
 +
==ٌReference==
 +
Wang, C. Y., Guo, H. Y., Lim, T. M., Ng, Y. K., Neo, H. P., Hwang, P. Y. K., ... & Wang, S. (2005). Improved neuronal transgene expression from an AAV‐2 vector with a hybrid CMV enhancer/PDGF‐β promoter. The Journal of Gene Medicine: A cross‐disciplinary journal for research on the science of gene transfer and its clinical applications, 7(7), 945-955.‏
 +
 +
Xu X, Gao J, Dai W, Wang D, Wu J, Wang J. Gene activation by a CRISPR-assisted trans enhancer. Elife. 2019 Apr 11;8:e45973. doi: 10.7554/eLife.45973. PMID: 30973327; PMCID: PMC6478495.
 +
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here
 
===Usage and Biology===
 
===Usage and Biology===

Latest revision as of 03:51, 26 September 2024


UAS Trans CMV enhancer

Part Description

it is a a Powerful Tool for Gene Expression which is derived from the cytomegalovirus (CMV). it can significantly boost gene expression in various cell types. it works by binding to specific transcription factors, which then recruit other proteins to the promoter region of a gene. This complex interaction helps to initiate and sustain gene transcription.

Usage

This part is fused with GAL4, dcas9(c), VP64. it acts as a powerful transcription activator where it induce transcription and increased gene expression so after receptor activation, it will be directed with dCas9,VP64 and GAL4 to increases expression of YAP.

Literature Characterization

Three AAV-2 vectors were created by inserting different promoters (CMV enhancer, PDGF, or a hybrid of the two) into a plasmid containing a firefly luciferase gene. These plasmids were then combined with two other plasmids (pAAV-RC and pHelper) and introduced into HEK293 cells which resulted in the production of three AAV-2 vectors, named AAV-CMV enhancer-luc, AAV-PDGF-luc, and AAV-CMV enhancer/PDGF-luc. The researchers tested how well the three AAV-2 vectors infected different types of cells, including primary rat brain cells (neurons and glial cells), and mouse and human cell lines (C17.2 and NT2-N) that had been grown to become neurons. They used a high dose (MOI of 1000) to ensure maximum infection.

AAV-2 vectors containing a hybrid CMV enhancer/PDGF promoter significantly increased luciferase gene expression in primary cortex neurons compared to vectors with the CMV enhancer/P promoter or the PDGF promoter alone respectively, at both 4 and 7 days post-transduction (Figures 1A and 1B).. This effect was seen in both mouse and human neuronal cells. However, in primary glial cells, the CMV enhancer/P promoter was more effective than the hybrid promoter(Figure 1C). These results suggest that the hybrid promoter retains its neuronal specificity.

Characterization by Mathematical Modeling

The model provides the activation kinetics of CMV trans-enhancer which occurs subsequent to upon releasing of the d-Cas9 system to initiate the transcription of the YAP-1.The result shows increase in transcription activation level of YAP-1 which implies successful CMV trans-enhancer activation based on parametric values from literature

Graph(1). Illustrates the relation between activation level of CMV trans-enhancer (Blue line) for increasing the transcription level of YAP-1 (Black line) .

ٌReference

Wang, C. Y., Guo, H. Y., Lim, T. M., Ng, Y. K., Neo, H. P., Hwang, P. Y. K., ... & Wang, S. (2005). Improved neuronal transgene expression from an AAV‐2 vector with a hybrid CMV enhancer/PDGF‐β promoter. The Journal of Gene Medicine: A cross‐disciplinary journal for research on the science of gene transfer and its clinical applications, 7(7), 945-955.‏

Xu X, Gao J, Dai W, Wang D, Wu J, Wang J. Gene activation by a CRISPR-assisted trans enhancer. Elife. 2019 Apr 11;8:e45973. doi: 10.7554/eLife.45973. PMID: 30973327; PMCID: PMC6478495.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]